Dooley v. Everett

805 S.W.2d 380, 1990 Tenn. App. LEXIS 856
CourtCourt of Appeals of Tennessee
DecidedDecember 12, 1990
StatusPublished
Cited by105 cases

This text of 805 S.W.2d 380 (Dooley v. Everett) is published on Counsel Stack Legal Research, covering Court of Appeals of Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dooley v. Everett, 805 S.W.2d 380, 1990 Tenn. App. LEXIS 856 (Tenn. Ct. App. 1990).

Opinion

OPINION

LEWIS, Judge.

The appeal in this case presents the issue of whether under the facts in the record there is a genuine issue of material fact regarding whether a pharmacist has a duty to warn a customer and/or the customer’s physician of the potential interaction between two different prescription drugs *382 written by the same physician on two different days and which are filled as written hy the same pharmacist on different days.

The trial court held there was no duty, sustained defendants’ Reveo Discount Drug Centers, Inc. and Reveo D.S., Inc.’s 1 motion for summary judgment and dismissed plaintiffs’ complaint.

The pertinent facts are as follows:

Dr. Leon Everett, a family practice physician in Lawrenceburg, Tennessee, began treating the minor plaintiff Brandon Dooley in June 1985 when Brandon was three years old. Brandon was hospitalized in June 1985 for pneumonia and, during this hospitalization, Dr. Everett prescribed an asthma medication known as Theophylline. In January 1986, Dr. Everett diagnosed Brandon as suffering from asthma and again prescribed Theophylline for Brandon.

Theophylline is a prescription only medication used in the treatment of asthma and has a recommended therapeutic range of ten to twenty micrograms per milliliter. A blood serum level of less than ten micrograms per milliliter is considered of no therapeutic value. Serum levels in excess of twenty micrograms per milliliter present potential toxicity. Reveo filled the Theo-phylline prescriptions prescribed by Dr. Everett at various times between 14 September 1987 and 23 December 1987. Dosages of Theophylline were increased from 150 mgs. twice a day to 200 mgs. three times a day by Dr. Everett.

On 17 December 1987, Dr. Everett prescribed Erythromycin for Brandon at 400 mgs. four times per day for a period of ten days. This prescription was filled by Rev-eo on 17 December 1987. At the time Erythromycin was prescribed for Brandon, he was still taking 200 mgs. of Theophyl-line three times per day as per Dr. Everett’s orders.

On 23 December 1987, Brandon suffered cerebral seizures as the result of toxic levels of Theophylline in his blood.

At the time Erythromycin was prescribed by Dr. Everett and the prescription was dispensed by Reveo, the package insert for Erythromycin provided in pertinent part:

Recent data from studies of Erythro-mycin reveal that its use in patients who are receiving high doses of Theophylline may be associated with an increase of serum Theophylline levels and potential Theophylline toxicity. In case of Theo-phylline toxicity and/or elevated serum Theophylline levels, the dose of Theo-phylline should be reduced while the patient is receiving concomitant Erythro-mycin therapy.

At the time Reveo filled the Erythromy-cin prescription, Reveo did not warn or explain the potential for interaction to the plaintiffs. Also, Reveo did not alert Dr. Everett of the potential interaction or possible effects of using Erythromycin concurrently with Theophylline.

Dr. Everett was familiar with the potential side effects resulting from the toxic serum levels of Theophylline in the blood. He knew these included nausea, vomiting and seizures.

The pharmacist on duty at the time Brandon’s prescription was delivered did not know that Erythromycin could interact with Theophylline. He did not know that this combination of drugs posed a risk of serious injury to Brandon.

In opposition to Revco’s motion for summary judgment, plaintiffs filed the affidavit of Roy E. Marcrom. Mr. Marcrom “received a Bachelor of Science Degree on Pharmacy” in 1971 and, in 1972, received a Doctor of Pharmacy Degree from the University of Tennessee. He has practiced pharmacy in Tennessee since his graduation and is presently the owner of Mar-crom’s Pharmacy in Manchester, Tennessee.

In his affidavit Mr. Marcrom states that “Pharmacy is a profession that requires considerable knowledge about drugs and how they affect the human body;” that “pharmacists recognize that there exists a *383 standard of care applicable to the practice of pharmacy in [Tennessee];” that “there are certain duties and responsibilities generally accepted by the members of the pharmacy community;” that the “accepted standard of care of professional practice for the profession of pharmacy as they existed in Lawrenceburg, Tennessee, and similar communities in 1987” included that “pharmacies maintain a patient profile system” and that “the patient profile should be reviewed by the pharmacist prior to filling a new prescription for several purposes” including a determination of whether the new drug prescribed for the patient and presented for filling to the pharmacist interacts with any other drug currently ordered for the patient. He further testified:

[T]he standard of care also required the pharmacist alerted to the interaction to call the Erythromycin prescriber, alert him or her to the potential interaction, and/or advise the patient or patient’s representative of the potential interaction and encourage him or her to (1) have his or her serum Theophylline levels monitored and/or (2) be alert for side effects of Theophylline toxicity. It is difficult to articulate what the standard of care requires of a pharmacist without knowing the exact circumstances under which the prescription for Ery-Ped was presented but, regardless of the circumstances, the pharmacist is required to alert the patient or patient’s representative to the potential interaction.

Mr. Marcrom also testified that “there exists and did exist in 1983, 1984, 1985, 1986, and 1987, computer technology which was available to pharmacists to identify drug interactions in general and the Eryth-romycin and Theophylline interaction in particular.”

Revco’s motion for summary judgment was made on the sole basis that as a matter of law the pharmacist does not have a duty to warn his customer that there exists a potential drug interaction.

In order for Reveo to prevail on its motion for summary judgment, it must establish that there is no genuine issue of material fact and that it is entitled to a judgment as a matter of law. Tenn.R.Civ.P. 56.03.

In determining whether or not a genuine issue of fact exists in a summary judgment ease, the trial court, and this Court on appeal, must look to all the evidence, take the strongest legitimate view of it in favor of the opponent of the motion and, allowing all reasonable inferences from it in his favor, discard all countervailing evidence. If then there is any dispute as to any material determinative evidence or any doubt as to the conclusion to be drawn from the whole evidence, the motion must be denied. See Phillips v. Pittsburg Consol. Coal Co., 541 S.W.2d 411, 413 (Tenn.1976). Where a dispute exists as to any material fact or where there is merely uncertainty as to whether there may be a dispute, it is the duty of the court to overrule a motion for summary judgment. Dolan v. Cunningham, 648 S.W.2d 652 (Tenn.App.1982).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Charles Huddleston Heaton Jr. v. Catherine L. Mathes
Court of Appeals of Tennessee, 2020
Gregory Websterv. David M. Isaacs
Court of Appeals of Tennessee, 2019
Harris v. Nationwide Mut. Fire Ins. Co.
367 F. Supp. 3d 768 (M.D. Tennessee, 2019)
Robert Eugene Hulan v. Coffee County Bank
Court of Appeals of Tennessee, 2019
Charles Webster v. Steve L. Walker
Court of Appeals of Tennessee, 2018
Oakey v. May Maple Pharmacy, Inc.
2017 NMCA 54 (New Mexico Court of Appeals, 2017)
Abrams v. Bute
138 A.D.3d 179 (Appellate Division of the Supreme Court of New York, 2016)
Zander v. Katz, Sapper & Miller, LLP
25 F. Supp. 3d 1055 (M.D. Tennessee, 2014)
Hardeman County v. Judy I. McIntyre
420 S.W.3d 742 (Court of Appeals of Tennessee, 2013)
Evelyn Nye v. Bayer Cropscience, Inc.
347 S.W.3d 686 (Tennessee Supreme Court, 2011)
Kowalski v. Rose Drugs of Dardanelle, Inc.
2011 Ark. 44 (Supreme Court of Arkansas, 2011)
Sanchez Ex Rel. Sanchez v. Wal-Mart
221 P.3d 1276 (Nevada Supreme Court, 2009)
Olinger v. University Medical Center
269 S.W.3d 560 (Court of Appeals of Tennessee, 2008)
Conley v. Life Care Centers of America, Inc.
236 S.W.3d 713 (Court of Appeals of Tennessee, 2007)
Kilgore v. Carson Pirie Holdings, Inc.
205 F. App'x 367 (Sixth Circuit, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
805 S.W.2d 380, 1990 Tenn. App. LEXIS 856, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dooley-v-everett-tennctapp-1990.